Novel Therapeutic for Pulmonary Arterial Hypertension

OCR Number: OCR 5799

Description:

- Pulmonary arterial hypertension (PAH) has limited treatment options with 40-50% mortality within 3 years of diagnosis.
- Identification of novel therapeutic targets remains a critical unmet medical need for this disease.
- The global market for PAH is expected to grow to over $3.5 billion by 2016.
- MicroRNAs (miRs) 424 and 503 are effective in human and animal models of PAH (see figure).
- miRs 424 and 503 may be the basis for effective therapeutics for PAH.

![Graph showing RI/SP (mm Hg) for different groups including GFP, 424/503-GFP, and 424/503-GFP with MCT Prevention and Rescue, and SuHx Rescue.]

Published/Issued Patents: U.S. Pub. App. No. 20140155459

Licensing Contact: John Puziss
john.puziss@yale.edu